Not obtaining a medication the first time it is prescribed: primary non-adherence to cardiovascular pharmacotherapy.

Schulz, M; Laufs, U

Not obtaining a medication the first time it is prescribed: primary non-adherence to cardiovascular pharmacotherapy.

Schulz, M

Laufs, U

Permalink

Publisher:: SPRINGER HEIDELBERG
Publication Type:: Journal Article
Citation:: Clin Res Cardiol, 2023
Issue Date:: 2023-05-20

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.21 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Schulz, M https://orcid.org/0000-0002-5876-7322
dc.contributor.author	Laufs, U
dc.date.accessioned	2023-11-06T23:21:39Z
dc.date.available	2023-05-08
dc.date.available	2023-11-06T23:21:39Z
dc.date.issued	2023-05-20
dc.identifier.citation	Clin Res Cardiol, 2023
dc.identifier.issn	1861-0684
dc.identifier.issn	1861-0692
dc.identifier.uri	http://hdl.handle.net/10453/173103
dc.description.abstract	Primary medication non-adherence describes the situation when a first prescription for a new medication is never filled. Primary non-adherence is an important, yet understudied aspect of reduced effectiveness of pharmacotherapy. This review summarizes the frequency, impact, reasons, predictors, and interventions regarding primary non-adherence to cardiovascular/cardiometabolic drugs. The current literature reveals a high prevalence of primary non-adherence. The individual risk of primary non-adherence is determined on multiple factors, e.g., primary non-adherence of lipid-lowering drugs is higher compared to antihypertensive medications. However, the overall rate of primary non-adherence is > 10%. Additionally, this review identifies specific areas for research to better understand why patients forgo evidence-based beneficial pharmacotherapy and to explore targeted interventions. At the same time, measures to reduce primary non-adherence-once proven to be effective-may represent an important new opportunity to reduce cardiovascular diseases.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	SPRINGER HEIDELBERG
dc.relation.ispartof	Clin Res Cardiol
dc.relation.isbasedon	10.1007/s00392-023-02230-3
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1102 Cardiorespiratory Medicine and Haematology
dc.subject.classification	Cardiovascular System & Hematology
dc.subject.classification	3201 Cardiovascular medicine and haematology
dc.title	Not obtaining a medication the first time it is prescribed: primary non-adherence to cardiovascular pharmacotherapy.
dc.type	Journal Article
utslib.location.activity	Germany
utslib.for	1102 Cardiorespiratory Medicine and Haematology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	open_access	*
dc.date.updated	2023-11-06T23:21:38Z
pubs.publication-status	Published online

Abstract:

Primary medication non-adherence describes the situation when a first prescription for a new medication is never filled. Primary non-adherence is an important, yet understudied aspect of reduced effectiveness of pharmacotherapy. This review summarizes the frequency, impact, reasons, predictors, and interventions regarding primary non-adherence to cardiovascular/cardiometabolic drugs. The current literature reveals a high prevalence of primary non-adherence. The individual risk of primary non-adherence is determined on multiple factors, e.g., primary non-adherence of lipid-lowering drugs is higher compared to antihypertensive medications. However, the overall rate of primary non-adherence is > 10%. Additionally, this review identifies specific areas for research to better understand why patients forgo evidence-based beneficial pharmacotherapy and to explore targeted interventions. At the same time, measures to reduce primary non-adherence-once proven to be effective-may represent an important new opportunity to reduce cardiovascular diseases.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/173103